Lilly's weight-loss pill wins US approval
Lilly's weight-loss pill wins US approval
By Leah Douglas and Christy SanthoshWed, April 1, 2026 at 3:44 PM UTC
0
FILE PHOTO: Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., September 23, 2025. REUTERS/Antranik Tavitian/File Photo
By Leah Douglas and Christy Santhosh
April 1 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Eli Lilly's weight-loss pill, making it the second to market after Novo Nordisk's oral Wegovy, as the companies fight to capture more customers with the convenience of pills over injectables.
Advertisement
The Lilly drug, orforglipron, which will be sold under the brand name Foundayo, is a once-daily oral medication designed to mimic the appetite-suppressing GLP-1 hormone targeted by the company's blockbuster injection tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss.
(Reporting by Leah Douglas in Washington and Christy Santhosh in Bengaluru; Editing by Bill Berkrot)
Source: “AOL Breaking”
